CHICAGO, IL USA (UroToday) - The interactive panel on sexual dysfunction in the prostate cancer patient, moderated by John Mulhall, MD, shared three perspectives: radical prostatectomy, androgen deprivation therapy, and radiation therapy.

CHICAGO, IL USA (UroToday) - This session reported on a study of 178 men to determine the optimal erectile function domain (EFD) score after radical prostatectomy against a sexual satisfaction rating system. An EFD score of 25 represents the optimum score for intercourse satisfaction.

CHICAGO, IL USA (UroToday) - This session provided a discussion of the transient change in erectile function and LUTS after prostate needle biopsy (PNBx). Some studies suggest this is related to the type of anesthesia used.

CHICAGO, IL USA (UroToday) - This session included previous research suggesting lower levels of serum bioavailable testosterone (bT) are associated with a greater prevalence of erectile dysfunction among men with newly diagnosed prostate cancer.

CHICAGO, IL USA (UroToday) - Mohit Khera, MD, reported an animal study of nitric oxide-releasing polymeric microspheres used as a therapy for erectile dysfunction.

CHICAGO, IL (UroToday.com) - Presented by Mary-Ellen Taplin, MD at the Annual Meeting of the American Society of Clinical Oncology (ASCO)- June 1 - 5, 2012 - McCormick Place - Chicago, IL USA.

BERKELEY, CA (UroToday.com) -

Presentation of the New Paradigms for Hormone Therapy in Prostate Cancer

BERKELEY, CA (UroToday.com) - June 21, 2012 - Translating the clinical results observed from pre-specified interim analyses of the randomized, placebo-controlled phase III study, COU-AA-302 demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS), and all secondary endpoints, compared to patients treated with placebo plus prednisone.

ATLANTA, GA USA (UroToday) - Presented by Inder Perkash, MD, FACS, FRCS* at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

ALEXANDERIA, VA USA (Press Release) - May 23, 2012

 −June 1-4: Onsite Press Conferences in Chicago−

ATLANTA, GA USA (UroToday) - Presented by Monique Roobol, PhD* (on behalf of the ERSPC Study Group) at the American Urological Association (AUA) Annual Meeting- May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

ATLANTA, GA USA (UroToday) - Presented by Oliver Sartor, MD* at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

ATLANTA, GA USA (UroToday) -

Aligning Treatment Goals Involves Patient-Physician Dialog

An interesting podium presentation by Brad Davidson, et al. addressed the absence of goal setting between metastatic prostate cancer (mCRPC) patients and their physicians. Keystone to this conversation is mutually defining the phrases “quality of life” versus “quantity of life.” Studies by Fowler (JAMA 2000) and Smith (J Supportive Oncology 2011) both reported patients are not distressed by prognostic and treatment information.

The researchers sought to understand how mCRPC patients and their physicians mutually discuss treatment goals. Clinic visits were videotaped with patient-physician consent. Of the 42-mCRPC clinic visits of which 69% were African American patients, 7 urologists and 7 oncologists were involved. In all of these visits, the discussion about patient goals for therapy or the terminal nature of their disease never took place. Physicians were interviewed by the research team following the patient visit and completed a standardized questionnaire. The urologists and oncologists in this study prioritized the care plan by preserving “quality of life.” In contrast, the patients were also independently interviewed and completed a questionnaire. These patients identified “quantify of life” to be most important. Both groups assumed their treatment goals were aligned. The absence of dialog engulfed the differences.

This study emphasizes the need to enhance communication between the patient and physician aligning treatment goals and defining expectations.

This study was support by Janssen Scientific Affairs.

Presented by Brad Davidson, Matthew DiChiara, Robert A Bailey, Lorie A Ellis, Mekre’ Senbetta, Andrew J Stephenson, and Tracey L Krupski at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

View full AUA Coverage

ATLANTA, GA USA (UroToday) -

Pre-operative Aspirin users have lower Serum PSA level than Non-users

The Duke Prostate Cancer Center study (Abstract 2237) investigated whether long-term aspirin use lowers serum PSA levels. Aspirin has been shown to be associated with reduced risk for several cancers including colorectal cancer. The group sought to understand the pharmacologic influence of aspirin on PSA levels.

The study group involved 931 men with prostate cancer undergoing prostatectomy. These men had known aspirin maintenance use prior to surgery. The group used a Mann-Whitney test to determine associations of aspirin use with PSA levels. Results showed 325 men (35%) were prescribed aspirin prior to the surgery. Aspirin users tended to be older and Caucasian compared to non-users. After controlling various clinical and pathological confounders, aspirin use was significantly associated with lower PSA levels. The mean-adjusted PSA for aspirin users was 4.95 and for non-users 5.41. The 8.5% reduction in aspirin users needs to be verified in other radical prostatectomy cohorts and men without prostate cancer.

Presented by Cagri Senocak, Lionel Banez, Jean-Alfred Thomas, Roberto Muller, Leah Gerber, Cary Robertson, Thomas Polascik, Stephen Freedland, Philip Walther, and Judd Moul at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

View full AUA Coverage

ATLANTA, GA USA (UroToday) -

Predictors for Prostate Cancer Candidate Selection

ATLANTA, GA USA (UroToday) - The burden of prostate cancer in the U.S. and Europe remains significant despite the fact that overall mortality has improved. Prostate cancer remains the second leading cause of cancer death in men.

ATLANTA, GA USA (UroToday) - Presented by Presented by Scott MacDiarmid, MD,¹ Melissa Martinson, PhD,² and Edward Black, MBA³ at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA at the American Urological Association (AUA) Annual Meeting- May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

ATLANTA, GA USA (UroToday) - INTRODUCTION AND OBJECTIVES: Neuromodulation for overactive bladder (OAB), including both electrical stimulation of nerves that control bladder function via direct implantable sacral nerve stimulation (SNS), or indirectly via percutaneous tibial nerve stimulation (PTNS), are increasingly recommended in the OAB treatment algorithm.

ATLANTA, GA USA (UroToday) - Presented by Scott MacDiarmid, MD,¹ Melissa Martinson, PhD,² and Edward Black, MBA³ at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

¹Alliance Urology Specialists, Greensboro, NC
²Technomics Research LLC, Minneapolis, MN
³Reimbursement Strategies LLC, St. Paul, MN

View full AUA Coverage

ATLANTA, GA USA (UroToday) - Presented by Kenneth M. Peters, MD,¹ Donna J. Carrico, NP, MS,¹ Scott MacDiarmid, MD,² Leslie Saltzstein Wooldridge, NP,³ and Ansar U. Khan MD⁴ at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA